Shares of Seattle, Washington-based Atossa Therapeutics (ATOS), a clinical-stage biopharmaceutical company researching treatments for both cancer and Covid-19, soared more than 9 times in value in the first six months of 2021... before abruptly turning tail and losing more than half their value over the last three months. That's bad news for anyone who bought the shares at their peak in mid-June -- but it could be great news for investors who buy Atossa stock today. Or so says Ascendiant analyst Edward Woo.
https://www.tipranks.com/news/article/3-reasons-to-love-atossa-therapeutics-stock?utm_source=advfn.com&utm_medium=referral